Clinical data | |
---|---|
Other names | Cepharantin, O-Methylcepharanoline |
AHFS/Drugs.com | International Drug Names |
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.208.632 |
Chemical and physical data | |
Formula | C37H38N2O6 |
Molar mass | 606.719 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Cepharanthine is an antiinflammatory and antineoplastic compound isolated from Stephania. Due to these modalities, it has been shown effective against HTLV in lab research. Additionally, it has successfully been used to treat a diverse range of medical conditions, including radiation-induced leukopenia, idiopathic thrombocytopenic purpura, alopecia areata, alopecia pityrodes, venomous snakebites, xerostomia, sarcoidosis, refractory anemia and various cancer-related conditions. No safety issues have been observed with CEP, and side effects are very rarely reported.
References
- Huang H, Hu G, Wang C, Xu H, Chen X, Qian A (February 2014). "Cepharanthine, an alkaloid from Stephania cepharantha Hayata, inhibits the inflammatory response in the RAW264.7 cell and mouse models". Inflammation. 37 (1): 235–46. doi:10.1007/s10753-013-9734-8. PMID 24045962. S2CID 7186762.
- Toyama M, Hamasaki T, Uto T, Aoyama H, Okamoto M, Hashmoto Y, Baba M (July 2012). "Synergistic inhibition of HTLV-1-infected cell proliferation by combination of cepharanthine and a tetramethylnaphthalene derivative". Anticancer Research. 32 (7): 2639–45. PMID 22753721.
- Rogosnitzky M, Danks R (2011). "Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions" (PDF). Pharmacological Reports. 63 (2): 337–47. doi:10.1016/S1734-1140(11)70500-X. PMID 21602589.
Non-steroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA) | |
---|---|
pyrazolones / pyrazolidines | |
salicylates | |
acetic acid derivatives and related substances | |
oxicams | |
propionic acid derivatives (profens) |
|
n-arylanthranilic acids (fenamates) | |
COX-2 inhibitors (coxibs) | |
other | |
NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; WHO-Essential Medicines; withdrawn drugs; veterinary use. | |
This drug article relating to the musculoskeletal system is a stub. You can help Misplaced Pages by expanding it. |
This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |